Business Wire

Qvest to Accelerate Generative AI for Media and Entertainment Businesses in Collaboration with NVIDIA

10.9.2024 16:03:00 EEST | Business Wire | Press release

Share

IBC2024 -- Qvest, a leading consultant and systems integrator in media-focused services, today announced a collaboration with NVIDIA to drive AI adoption in the media and entertainment industry. These solutions powered by generative AI (GenAI), will create new opportunities for revenue generation, customer engagement, and operational efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910864873/en/

Christophe Ponsart - EVP and Applied AI Practice Co-Lead, Qvest US. (Photo: Business Wire)

Qvest is expanding its alliance program in artificial intelligence to further position the company as a leader in AI for media businesses. By fostering collaboration across industries and leveraging shared expertise, Qvest delivers tangible GenAI applications that drive ROI.

The collaboration with NVIDIA combines Qvest’s deep expertise in media and entertainment with NVIDIA’s leading AI capabilities and technology platform. This will deliver advanced AI-driven solutions that empower companies to harness the full potential of GenAI.

Using NVIDIA's AI technologies, Qvest is further developing GenAI offerings in its Applied AI practice that address the key business challenges of media companies and help increase their productivity, promote creativity and optimize processes.

“The collaboration with NVIDIA enables us to quickly deliver powerful use cases for media and entertainment companies. Together, we are helping our customers generate value from AI in areas most impactful for their business,” said Christophe Ponsart, EVP and Applied AI Practice Co-Lead, Qvest US.

A GenAI solution will be unveiled at the IBC Show in Amsterdam, streamlining content management and creation within existing media workflows for:

  • Automated Metadata Tagging: Drastically reduces time and costs associated with manual cataloging by automating structured metadata tagging across multiple modalities (text, audio, vision).
  • Accelerated Content Discovery: User enablement to quickly find relevant content across and within video assets.
  • Empowered Content Generation: Generation and iteration on contextually relevant headlines, scripts, and narratives in seconds to accelerate time to market.

“Media and entertainment companies are looking to accelerate AI adoption to deliver enhanced experiences. By combining NVIDIA’s AI platform with Qvest’s industry expertise, Qvest is empowering customers to quickly move from idea to scalable implementation using the latest developments in AI,” said Richard Kerris, Vice President of Media and Entertainment at NVIDIA.

NVIDIA NIM inference microservices play a critical role in this collaboration, offering seamless hosting of state-of-the-art GenAI models for computer vision, content generation, audio transcription, and more. Companies can choose where to run their models, whether in the cloud or hosted locally, helping ensure that data remains secure while optimizing performance.

Qvest is committed to continuing its collaboration with NVIDIA, with plans to integrate NVIDIAHoloscan for Media, an AI-enabled, software-defined platform for live media, for real-time streaming ingestion and content discovery. This integration will help further enhance the capabilities of GenAI infrastructure, increasing security, reducing costs, boosting performance, and minimizing operational overhead.

Qvest’s GenAI accelerators, developed in collaboration with NVIDIA, will be showcased at IBC 2024, where attendees can experience a full range of tangible and practical GenAI use cases firsthand at Qvest’s booth (#10.C24). More about Qvest at IBC2024 at www.qvest.com/ibc2024

About Qvest

Qvest is a global leader in media-focused practices and services. Qvest supports companies holistically in their Digital Transformation with innovation, consulting and technology implementation services to achieve future-oriented change. With deep expertise in media, information and communications technology, Qvest supports its customers in transforming their business towards digitalization, cloud and AI. Qvest's customers include numerous global brands from industries such as media & entertainment, telecommunications, automotive, health & pharmaceuticals, consumer goods, retail, transportation, and logistics, as well as organizations from the public sector. In addition to its headquarters in Germany, the company operates locations across Europe, the USA, the Middle East, Southeast Asia, and Australia.

www.qvest.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910864873/en/

Contacts

Qvest Group GmbH
Christian Felder
Tel.: +49 174 9481 983
E-Mail: christian.felder@qvest.com
Web: www.qvest.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qvest.com&e
sheet=54119793&newsitemid=20240910864873&lan=en-US&anchor=www.qvest.com&index=3&
md5=c0a5bdcc8dfc89ea26ad0ef9f0362b7d

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye